The noncoding-RNA landscape in cardiovascular health and disease

Non-coding RNA Research

Volumn 3, Issue 1, 2018, Pages 12-19

  Di Mauro, Vittoria ^a,b   Barandalla Sobrados, Maria ^a,b   Catalucci, Daniele ^a,b  

^a Milan Unit   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LONG UNTRANSLATED RNA; MICRORNA; NANOPARTICLE; PIWI INTERACTING RNA; RNA INDUCED SILENCING COMPLEX; RNA POLYMERASE II; SMALL NUCLEAR RNA; TRANSFER RNA; UNTRANSLATED RNA;

APOPTOSIS; BIOGENESIS; CARDIOVASCULAR DISEASE; DNA REPLICATION; DOWN REGULATION; EXPRESSION VECTOR; GENE ACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; MRNA EXPRESSION LEVEL; NANOMEDICINE; NONHUMAN; OPEN READING FRAME; REVIEW; RNA INTERFERENCE; RNA STABILITY; RNA TRANSLATION; SIGNAL TRANSDUCTION;

EID: 85049136858     PISSN: 24680540     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncrna.2018.02.001     Document Type: Review

References (121)

1. Olson, E.N., A decade of discoveries in cardiac biology. Nat. Med. 10:5 (2004), 467–474.
2. Ptaszek, L.M., et al. Towards regenerative therapy for cardiac disease. Lancet 379:9819 (2012), 933–942.
3. Ho, Y.T., Poinard, B., Kah, J.C.Y., Nanoparticle drug delivery systems and their use in cardiac tissue therapy. Nanomedicine 11:6 (2016), 693–714.
4. Hastings, C.L., et al. Drug and cell delivery for cardiac regeneration. Adv. Drug Deliv. Rev. 84 (2015), 85–106.
5. Poller, W., et al. Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. Cardiovasc. Res. 86:3 (2010), 353–364.
6. Ounzain, S., Crippa, S., Pedrazzini, T., Small and long non-coding RNAs in cardiac homeostasis and regeneration. Biochim. Biophys. Acta Mol. Cell Res. 1833:4 (2013), 923–933.
7. Honig, P., Terzic, A., Affairs of the Heart: innovation in cardiovascular research and development. Clin. Pharmacol. Therapeut. 102:2 (2017), 162–168.
8. McCormack, P.L., Sacubitril/valsartan: a review in chronic heart failure with reduced ejection fraction. Drugs 76:3 (2016), 387–396.
9. Ottaviani, L., da Costa Martins, P.A., Non-coding RNAs in cardiac hypertrophy. J. Physiol. 595:12 (15 June 2017), 4037–4050.
10. Kataoka, M., Wang, D.-Z., Non-coding RNAs including miRNAs and lncRNAs in cardiovascular biology and disease. Cells 3:3 (2014), 883–898.
11. Frank, S., et al. A lncRNA perspective into (Re) building the heart. Front. Cell. Dev. Biol., 2016, 4.
12. Beermann, J., et al. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol. Rev. 96:4 (2016), 1297–1325.
13. Chatterjee, S., Bär, C., Thum, T., Linc-ing the noncoding genome to heart function: beating hypertrophy. Trends Mol. Med. 23:7 (July 2017), 577–579.
14. Poller, W., et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur. Heart J., 2017, ehx165, 10.1093/eurheartj/ehx165 [Epub ahead of print].
15. Huang, M.-S., et al. LncRNAs and CircRNAs from the same gene: masterpieces of RNA splicing. Canc. Lett. 415 (28 February 2018), 49–57.
16. Choong, O.K., et al. The roles of non-coding RNAs in cardiac regenerative medicine. Non-coding RNA Research 2:2 (June 2017), 100–110.
17. Grishok, A., et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 106:1 (2001), 23–34.
18. Van Rooij, E., Olson, E.N., microRNAs put their signatures on the heart. Physiol. Genom. 31:3 (2007), 365–366.
19. Han, M., Toli, J., Abdellatif, M., MicroRNAs in the cardiovascular system. Curr. Opin. Cardiol. 26:3 (2011), 181–189.
20. Kim, V.N., Nam, J.-W., Genomics of microRNA. Trends Genet. 22:3 (2006), 165–173.
21. Ha, M., Kim, V.N., Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15:8 (2014), 509–524.
22. Di Mauro, V., Catalucci, D., The importance of being ncRNAs: from bit players as “junk DNA” to rising stars on the stage of the pharmaceutical industry. Ann. Transl. Med., 5(6), 2017.
23. Mirra, P., et al. Circulating miRNAs as Intercellular messengers, Potential Biomarkers and Therapeutic Targets for Type 2 Diabetes. 2015.
24. Chen, X., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res., 18(10), 2008.
25. Hunter, M.P., et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One, 3(11), 2008, e3694.
26. Skog, J., et al. Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers. Nat. Cell Biol., 10(12), 2008, 1470.
27. Catalanotto, C., Cogoni, C., Zardo, G., MicroRNA in control of gene expression: an overview of nuclear functions. Int. J. Mol. Sci., 17(10), 2016, 1712.
28. Roberts, T.C., The microRNA biology of the mammalian nucleus. Mol. Ther. Nucleic Acids, 3(8), 2014, e188.
29. Rajan, K.S., et al. Abundant and altered expression of PIWI-Interacting RNAs during cardiac hypertrophy. Heart Lung Circ. 25:10 (2016), 1013–1020.
30. Thomson, T., Lin, H., The biogenesis and function of PIWI proteins and piRNAs: progress and prospect. Annu. Rev. Cell. Dev. 25 (2009), 355–376.
31. Vella, S., et al. PIWI-interacting RNA (piRNA) signatures in human cardiac progenitor cells. Int. J. Biochem. Cell Biol. 76 (2016), 1–11.
32. Rajan, K.S., et al. miRNA and piRNA mediated Akt pathway in heart: antisense expands to survive. Int. J. Biochem. Cell Biol. 55 (2014), 153–156.
33. Katz, A., et al. Non-canonical roles of tRNAs and tRNA mimics in bacterial cell biology. Mol. Microbiol. 101:4 (2016), 545–558.
34. Schimmel, P., The emerging complexity of the tRNA world: mammalian tRNAs beyond protein synthesis. Nat. Rev. Mol. Cell Biol. 19 (2018), 45–58, 10.1038/nrm.2017.77.
35. Scott, M.S., Ono, M., From snoRNA to miRNA: dual function regulatory non-coding RNAs. Biochimie 93:11 (2011), 1987–1992.
36. Holley, C.L., Topkara, V.K., An introduction to small non-coding RNAs: miRNA and snoRNA. Cardiovasc. Drugs Ther., 25(2), 2011, 151.
37. Mihailescu, R., Gene expression regulation: lessons from noncoding RNAs. RNA 21:4 (2015), 695–696.
38. Devaux, Y., et al. Long noncoding RNAs in cardiac development and ageing. Nat. Rev. Cardiol. 12:7 (2015), 415–425.
39. Cabili, M.N., et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes. Dev. 25:18 (2011), 1915–1927.
40. Quinn, J.J., Chang, H.Y., Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 17:1 (2016), 47–63.
41. Mitchell Guttman, I.A., et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature, 458(7235), 2009, 223.
42. Derrien, T., et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 22:9 (2012), 1775–1789.
43. Kumarswamy, R., et al. The circulating long non-coding RNA LIPCAR predicts survival in heart failure patients. Circ. Res. 114 (2014), 1569–1575 p. CIRCRESAHA. 114.303915.
44. Qi, P., Zhou, X.-y., Du, X., Circulating long non-coding RNAs in cancer: current status and future perspectives. Mol. Canc., 15(1), 2016, 39.
45. Clemson, C.M., et al. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Molecular cell 33:6 (2009), 717–726.
46. Skroblin, P., Mayr, M., “Going long”: long non-coding RNAs as biomarkers. Circ. Res. 115:7 (2014), 607–609.
47. Salzman, J., et al. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One, 7(2), 2012, e30733.
48. Jeck, W.R., et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. Rna 19:2 (2013), 141–157.
49. Cocquerelle, C., et al. Mis-splicing yields circular RNA molecules. Faseb. J. 7:1 (1993), 155–160.
50. Kelly, S., et al. Exon skipping is correlated with exon circularization. Journal of molecular biology 427:15 (2015), 2414–2417.
51. Memczak, S., et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495:7441 (2013), 333–338.
52. Guo, J.U., et al. Expanded identification and characterization of mammalian circular RNAs. Genome biology, 15(7), 2014, 409.
53. Hansen, T.B., et al. Natural RNA circles function as efficient microRNA sponges. Nature 495:7441 (2013), 384–388.
54. Li, Z., et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat. Struct. Mol. Biol. 22:3 (2015), 256–264.
55. Lee, R.C., Feinbaum, R.L., Ambros, V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:5 (1993), 843–854.
56. Pasquinelli, A.E., et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature, 408(6808), 2000, 86.
57. Ardekani, A.M., Naeini, M.M., The role of microRNAs in human diseases. Avicenna J. Med. Biotechnol. (AJMB), 2(4), 2010, 161.
58. Barwari, T., Joshi, A., Mayr, M., MicroRNAs in cardiovascular disease. J. Am. Coll. Cardiol. 68:23 (2016), 2577–2584.
59. Kumarswamy, R., Thum, T., Non-coding RNAs in cardiac remodeling and heart failure. Circ. Res. 113:6 (2013), 676–689.
60. van Rooij, E., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. Unit. States Am. 103:48 (2006), 18255–18260.
61. van Rooij, E., Olson, E.N., MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11:11 (2012), 860–872.
62. Care, A., et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13:5 (2007), 613–618.
63. Castaldi, A., et al. MicroRNA-133 modulates the β1-adrenergic receptor transduction cascade. Circ. Res. 115:2 (2014), 273–283.
64. Thum, T., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456:7224 (2008), 980–984.
65. Kazemzadeh, M., Safaralizadeh, R., Orang, A.V., LncRNAs: emerging players in gene regulation and disease pathogenesis. J. Genet. 94:4 (2015), 771–784.
66. Scheuermann, J.C., Boyer, L.A., Getting to the heart of the matter: long non-coding RNAs in cardiac development and disease. EMBO J. 32:13 (2013), 1805–1816.
67. Klattenhoff, C.A., et al. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 152:3 (2013), 570–583.
68. Rotini, A., et al. Interactions between microRNAs and long non-coding RNAs in cardiac development and repair. Pharmacol. Res. 127 (January 2018), 58–66.
69. Han, P., et al. A long non-coding RNA protects the heart from pathological hypertrophy. Nature, 514(7520), 2014, 102.
70. Micheletti, R., et al. The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci. Transl. Med., 9(395), 2017 p. eaai9118.
71. Yoon, J.-H., Abdelmohsen, K., Gorospe, M., Functional interactions among microRNAs and long noncoding RNAs. Seminars in Cell & Developmental Biology, 2014, Elsevier.
72. Yoon, J.-H., et al. LincRNA-p21 suppresses target mRNA translation. Molecular cell 47:4 (2012), 648–655.
73. Wu, G., et al. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis and atherosclerosis by enhancing p53 activity. Circulation 130 (2014), 1452–1465 p. CIRCULATIONAHA. 114.011675.
74. Wang, K., et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489Novelty and significance. Circ. Res. 114:9 (2014), 1377–1388.
75. Faghihi, M.A., et al. Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol., 11(5), 2010, R56.
76. Panizo, S., et al. MicroRNAs 29b, 133b, and 211 regulate vascular smooth muscle calcification mediated by high phosphorus. J. Am. Soc. Nephrol. 27:3 (March 2016), 824–834 p. ASN. 2014050520.
77. Liu, N., et al. microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J. Clin. Invest., 122(6), 2012, 2054.
78. Poller, W., Fechner, H., Development of novel cardiovascular therapeutics from small regulatory RNA molecules-an outline of key requirements. Curr. Pharmaceut. Des. 16:20 (2010), 2252–2268.
79. Ebert, M.S., Neilson, J.R., Sharp, P.A., MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nature methods 4:9 (2007), 721–726.
80. Choi, W.-Y., Giraldez, A.J., Schier, A.F., Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 318:5848 (2007), 271–274.
81. Gumireddy, K., et al. Small-molecule inhibitors of MicroRNA miR-21 function. Angew. Chem. Int. Ed. 47:39 (2008), 7482–7484.
82. Garzon, R., Marcucci, G., Croce, C.M., Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9:10 (2010), 775–789.
83. Elmén, J., et al. LNA-mediated microRNA silencing in non-human primates. Nature 452:7189 (2008), 896–899.
84. Bonauer, A., et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324:5935 (2009), 1710–1713.
85. Tili, E., et al. miRNAs and Their Potential for Use against Cancer and Other Diseases. 2007.
86. Krützfeldt, J., et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438:7068 (2005), 685–689.
87. Doench, J.G., Petersen, C.P., Sharp, P.A., siRNAs can function as miRNAs. Genes. Dev. 17:4 (2003), 438–442.
88. Stenvang, J., et al. Inhibition of microRNA function by antimiR oligonucleotides. Silence, 3(1), 2012, 1.
89. Van Rooij, E., Marshall, W.S., Olson, E.N., Toward MicroRNA–based therapeutics for heart disease. Circ. Res. 103:9 (2008), 919–928.
90. Wang, S., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15:2 (2008), 261–271.
91. Rupaimoole, R., Slack, F.J., MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16:3 (2017), 203–222.
92. Chen, Y., et al. Bottleneck limitations for microRNA-based therapeutics from bench to the bedside. Die Pharmazie-An Int J Pharmaceut. Sci. 70:3 (2015), 147–154.
93. Hacein-Bey-Abina, S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:5644 (2003), 415–419.
94. Grote, P., et al. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev. Cell 24:2 (2013), 206–214.
95. Ren, S., et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J. Urol. 190:6 (2013), 2278–2287.
96. Sánchez, Y., Huarte, M., Long non-coding RNAs: challenges for diagnosis and therapies. Nucleic Acid Therapeut. 23:1 (2013), 15–20.
97. Lennox, K.A. and M.A. Behlke, Mini-review Open Access.
98. Ounzain, S., et al. CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. J. Mol. Cell. Cardiol. 89 (2015), 98–112.
99. Colley, S.M., Leedman, P.J., SRA and its binding partners: an expanding role for RNA-binding coregulators in nuclear receptor-mediated gene regulation. Crit. Rev. Biochem. Mol. Biol. 44:1 (2009), 25–33.
100. Tsai, M.-C., Spitale, R.C., Chang, H.Y., Long intergenic noncoding RNAs: new links in cancer progression. Canc. Res. 71:1 (2011), 3–7.
101. Parasramka, M.A., et al. Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. Pharmacol. Therapeut. 161 (2016), 67–78.
102. Moghimi, S.M., Hunter, A.C., Murray, J.C., Nanomedicine: current status and future prospects. The FASEB J 19:3 (2005), 311–330.
103. Riehemann, K., et al. Nanomedicine—challenge and perspectives. Angew. Chem. Int. Ed. 48:5 (2009), 872–897.
104. Ali, I., et al. Advances in nano drugs for cancer chemotherapy. Curr. Cancer Drug Targets 11:2 (2011), 135–146.
105. Blanco, E., Shen, H., Ferrari, M., Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33:9 (2015), 941–951.
106. Petros, R.A., DeSimone, J.M., Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9:8 (2010), 615–627.
107. Choi, H.S., et al. Renal clearance of quantum dots. Nat. Biotechnol. 25:10 (2007), 1165–1170.
108. Vinogradov, S.V., Bronich, T.K., Kabanov, A.V., Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliv. Rev. 54:1 (2002), 135–147.
109. Ilium, L., et al. Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. Int. J. Pharm. 12:2–3 (1982), 135–146.
110. Moghimi, S.M., et al. An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim. Biophys. Acta Gen. Subj. 1157:2 (1993), 233–240.
111. Di Mauro, V., et al. Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs. Nanomedicine 11:8 (2016), 891–906.
112. Black, K.C., et al. Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. ACS Nano 8:5 (2014), 4385–4394.
113. Yamamoto, Y., et al. Long-circulating poly (ethylene glycol)–poly (d, l-lactide) block copolymer micelles with modulated surface charge. J. Contr. Release 77:1 (2001), 27–38.
114. Miragoli, M., Ceriotti, P., Iafisco, M., Vacchiano, M., Salvarani, N., Alogna, A., Carullo, P., Ramirez-Rodríguez, G.B., Patrício, T., Esposti, L.D., Rossi, F., Ravanetti, F., Pinelli, S., Alinovi, R., Erreni, M., Rossi, S., Condorelli, G., Post, H., Tampieri, A., Catalucci, D., Inhalation of peptide-loaded nanoparticles improves heart failure. Sci. Transl. Med., 10(424), 17 Jan 2018, eaan6205, 10.1126/scitranslmed.aan6205.
115. Biray Avcı Ç., et al. Design of polyethylene glycol–polyethylenimine nanocomplexes as non-viral carriers: mir-150 delivery to chronic myeloid leukemia cells. Cell Biol. Int. 37:11 (2013), 1205–1214.
116. Wu, Y., et al. Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer. Mol. Ther. Nucleic Acids, 2, 2013, e84.
117. Mukhopadhyay, A., Weiner, H., Delivery of drugs and macromolecules to mitochondria. Adv. Drug Deliv. Rev. 59:8 (2007), 729–738.
118. Boddapati, S.V., et al. Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett. 8:8 (2008), 2559–2563.
119. Terlecky, S.R., Koepke, J.I., Drug delivery to peroxisomes: employing unique trafficking mechanisms to target protein therapeutics. Adv. Drug Deliv. Rev. 59:8 (2007), 739–747.
120. Zhang, Z., et al. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew. Chem. Int. Ed. 48:48 (2009), 9171–9175.
121. Matsui, M., Corey, D.R., Non-coding RNAs as drug targets. Nat. Rev. Drug Discov. 16 (2017), 167–179, 10.1038/nrd.2016.117.